Loading
Indian trials have shown that tiny daily doses of old oral chemotherapy drugs can help patients with head and neck cancer at a cost of a few dollars a month. These regimens should be proven and adopted worldwide.
Tata Memorial Centre's randomised trials of low-dose oral metronomic chemotherapy (methotrexate plus celecoxib, later triple metronomic therapy) in head and neck cancer reported survival comparable or superior to intravenous cisplatin in palliative settings at a fraction of the cost, and low-dose nivolumab added to metronomic therapy improved survival in another trial. These results have had limited uptake outside India. The proposal is a coordinated programme of confirmatory phase 3 trials in several LMICs across common cancers (head and neck, cervical, breast), with an explicit path to WHO essential medicines listing and guideline inclusion.
Shares Tata Memorial Centre, Chemotherapy roadmap: mustard gas → curative combinations → the warhead inside smarter drugs, No incentive to repurpose cheap drugs, Global access and affordability roadmap: essential medicines and generics → biosimilars and frugal trials → reliance, pooling and homegrown innovation.
Shares The Repurposing Drugs in Oncology (ReDO) Project, Chemotherapy roadmap: mustard gas → curative combinations → the warhead inside smarter drugs, No incentive to repurpose cheap drugs, Most of the world has almost no cancer care.
Shares Chemotherapy roadmap: mustard gas → curative combinations → the warhead inside smarter drugs, No incentive to repurpose cheap drugs, Most of the world has almost no cancer care.
Shares Chemotherapy roadmap: mustard gas → curative combinations → the warhead inside smarter drugs, Global access and affordability roadmap: essential medicines and generics → biosimilars and frugal trials → reliance, pooling and homegrown innovation, Most of the world has almost no cancer care, Cytotoxic chemotherapy.
Shares Tata Memorial Centre, Chemotherapy roadmap: mustard gas → curative combinations → the warhead inside smarter drugs, No incentive to repurpose cheap drugs, Global access and affordability roadmap: essential medicines and generics → biosimilars and frugal trials → reliance, pooling and homegrown innovation.
Shares The Repurposing Drugs in Oncology (ReDO) Project, Tata Memorial Centre, No incentive to repurpose cheap drugs.
Shares The Repurposing Drugs in Oncology (ReDO) Project, No incentive to repurpose cheap drugs.
Shares The Repurposing Drugs in Oncology (ReDO) Project, No incentive to repurpose cheap drugs.